Received Jul 3, 2026
Reports are unverified and do not show that a vaccine caused an event. Full disclaimer
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 1 | z010142 | — |
| HEP | HEP B (RECOMBIVAX HB) | MERCK & CO. INC. | 2 | a004329 | — |
No additional adverse event; a 30 year old female received their first dose of RECOMBIVAX HB 11/13/2026 and did not receive their second dose until 07/02/2026.; This spontaneous report was received from a other health professional and refers to a 30-year-old female patient. The patient's medical history, current conditions and concomitant therapies were not reported. On 13-NOV-2025 (conflicting information), the patient was vaccinated with first dose of Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB) (exact dose, anatomical route of administration, were not reported) (lot #z010142, who had been verified to be a valid lot number, formulation as syringe, expiration date assessed as 09-Feb-2028), and on 02-Jul-2026, the patient was vaccinated with second dose of Hepatitis B Vaccine (Recombinant) (exact dose, anatomical route of administration, were not reported) (lot # a004329, who had been verified to be a valid lot number, formulation as syringe, expiration date assessed as 20-Sep-2028). Both vaccines were administered as prophylaxis (Inappropriate schedule of product administration). No adverse event.